Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1411-1420 of 1,467) with videos related to

Pageof 147
Sort By:
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases|May 22, 2020
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateLaure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|April 18, 2014
Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceRonald F van Vollenhoven, Marta Mosca, George Bertsias, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Annals of the Rheumatic Diseases|September 29, 2011
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesL Gossec, J S Smolen, C Gaujoux-Viala, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growthAli Rashidfarrokhi, Ray Pillai, Yuan Hao, et al.
Annals of the Rheumatic Diseases|November 23, 2012
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsJosef S Smolen, Monika M Schoels, Norihiro Nishimoto, et al.
Arthritis and Rheumatism|September 28, 2010
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeDaniel Aletaha, Tuhina Neogi, Alan J Silman, et al.
Pageof 147

Showing results (1411-1420 of 1,467) with videos related to

Sort By:
Pageof 147
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases|May 22, 2020
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateLaure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|April 18, 2014
Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceRonald F van Vollenhoven, Marta Mosca, George Bertsias, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Annals of the Rheumatic Diseases|September 29, 2011
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesL Gossec, J S Smolen, C Gaujoux-Viala, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growthAli Rashidfarrokhi, Ray Pillai, Yuan Hao, et al.
Annals of the Rheumatic Diseases|November 23, 2012
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsJosef S Smolen, Monika M Schoels, Norihiro Nishimoto, et al.
Arthritis and Rheumatism|September 28, 2010
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeDaniel Aletaha, Tuhina Neogi, Alan J Silman, et al.
Pageof 147